IMR Press / FBL / Volume 12 / Issue 13 / DOI: 10.2741/2447

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Hepsin and prostate cancer
Show Less
1 Departments of Molecular Cardiology, Nephrology and Hypertension, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2 Department of Cancer Research, Berlex Biosciences, Richmond, CA 94806, USA
Front. Biosci. (Landmark Ed) 2007, 12(13), 5052–5059; https://doi.org/10.2741/2447
Published: 1 September 2007
Abstract

Hepsin is a membrane serine protease expressed in several human tissues including the liver, kidney, prostate, and thyroid. The physiological function of hepsin remains unknown. In vitro studies have shown that hepsin activates blood clotting factors VII, XII, and IX, pro-urokinase (pro-uPA), and pro-hepatocyte growth factor (pro-HGF). Recently, hepsin has been identified as one of the most up-regulated genes in prostate cancer. The hepsin up-regulation appears to correlate with the disease progression. In a mouse model of prostate cancer, hepsin overexpression promotes cancer progression and metastasis. In culture, anti-hepsin antibodies inhibited the invasion of human prostate cancer cells. This review will outline the molecular biology and biochemistry of hepsin and highlight recent data of hepsin in prostate cancer.

Keywords
Hepsin
Prostate Cancer
Type II Transmembrane Serine Protease
Drug Target
Review
Share
Back to top